<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="381">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on March 04, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787159</url>
  </required_header>
  <id_info>
    <org_study_id>EC-ID21</org_study_id>
    <nct_id>NCT04787159</nct_id>
  </id_info>
  <brief_title>Endometrial Cancer International Database</brief_title>
  <acronym>ECID</acronym>
  <official_title>Endometrial Cancer, a New Prospective Towards an Individually Adjusted Management Plans: A Multicenter International Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Middle-East OBGYN Graduate Education Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project aims to determining prognostic factors and individualizing management decision&#xD;
      per patient characteristics and endometrial cancer features. This study will include at least&#xD;
      10 centers from different countries that present at least Europe, South America, Asia, and&#xD;
      Africa. Data will be retrospectively collected from January 2008 to December 2015 with a&#xD;
      total follow-up of at least 5 years (December 2020).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometrial cancer (EC) or carcinoma of corpus uteri is a neoplastic change, mostly&#xD;
      adenocarcinoma, arising from uterine columnar epithelial lining. Abnormal uterine bleeding is&#xD;
      the main presenting symptom especially in postmenopausal women. EC is estimated to be the&#xD;
      seventh most commonly diagnosed cancer in women. It is considered the 16th leading cause of&#xD;
      death in women with cancer worldwide, with 382 000 estimated new cases and 89 900 deaths in&#xD;
      2018. Factors as obesity, parity, diabetes mellitus, unopposed estrogen exposure, genetics&#xD;
      and hormonal therapies are recognizable risks for EC. Other factors as chronic comorbidities,&#xD;
      tumor size and organ metastasis influence staging, prognosis, and management protocols.&#xD;
&#xD;
      FIGO staging has been adopted as the standard classification system in the management of&#xD;
      endometrial cancer. However, this staging system does not consider all factors that affect&#xD;
      treatment decision and prognosis including but not limited to patient demographics, tumor&#xD;
      grade, and lymphovascular space invasion. In addition, some interventions are still debatable&#xD;
      particularly in the presence of intermediate disease e.g, grade II early EC. Available&#xD;
      evidence supports combined pelvic and para-aortic lymphadenectomy in management of patients&#xD;
      with EC. However, combined pelvic and para-aortic lymphadenectomy carry the risk of long term&#xD;
      morbidities as lymphedema. Thus, hysterectomy alone as management plan is suggested in&#xD;
      patients with low risk EC. More comprehensive studies of the multiple confounders that&#xD;
      determine patient's risk are essential to reach an individually adjusted management plans and&#xD;
      to predict prognosis of each individual case. Therefore, availability of large multicenter&#xD;
      studies will provide robust evidence regarding optimal management of EC and hence, improve&#xD;
      treatment outcome and prognosis particularly in the era of machine learning and artificial&#xD;
      intelligence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival at 1 year</measure>
    <time_frame>At 1 year</time_frame>
    <description>Number of women who are alive after cancer treatment divided by total number of patients at study onset</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival at 3 years</measure>
    <time_frame>At 3 years</time_frame>
    <description>Number of women who are alive after cancer treatment divided by total number of patients at study onset</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival at 5 years</measure>
    <time_frame>At 5 years</time_frame>
    <description>Number of women who are alive after cancer treatment divided by total number of patients at study onset</description>
  </primary_outcome>
  <primary_outcome>
    <measure>disease free survival at 1 year</measure>
    <time_frame>At 1 year</time_frame>
    <description>Number of women who are are disease free after cancer treatment divided by total number of patients at study onset</description>
  </primary_outcome>
  <primary_outcome>
    <measure>disease free survival at 3 years</measure>
    <time_frame>At 3 years</time_frame>
    <description>Number of women who are are disease free after cancer treatment divided by total number of patients at study onset</description>
  </primary_outcome>
  <primary_outcome>
    <measure>disease free survival at 5 years</measure>
    <time_frame>At 5 years</time_frame>
    <description>Number of women who are are disease free after cancer treatment divided by total number of patients at study onset</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Endometrial Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All women who were diagnosed with endometrial cancer at any stage, of all histological&#xD;
        types and grades, between 2008 and 2015.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women diagnosed with endometrial cancer, between 2008 and 2015.&#xD;
&#xD;
          -  Women should be diagnosed and managed by the corresponding center.&#xD;
&#xD;
          -  Patients with adequate clinical and pathological data.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inadequate information and follow-up for at least 5 years.&#xD;
&#xD;
          -  Authorization to use anonymous patient data for research purposes.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherif A Shazly, M.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherif A Shazly, M.Sc</last_name>
    <phone>+15075131392</phone>
    <email>sherif.shazly.mogge@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Esraa M Hosny</last_name>
    <phone>01112969235</phone>
    <email>esraa.hosny.mogge@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Bell DW, Ellenson LH. Molecular Genetics of Endometrial Carcinoma. Annu Rev Pathol. 2019 Jan 24;14:339-367. doi: 10.1146/annurev-pathol-020117-043609. Epub 2018 Oct 17. Review.</citation>
    <PMID>30332563</PMID>
  </reference>
  <reference>
    <citation>Lax SF. [New features in the 2014 WHO classification of uterine neoplasms]. Pathologe. 2016 Nov;37(6):500-511. Review. German.</citation>
    <PMID>27738815</PMID>
  </reference>
  <reference>
    <citation>Hamilton CA, Pothuri B, Arend RC, Backes FJ, Gehrig PA, Soliman PT, Thompson JS, Urban RR, Burke WM. Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II. Gynecol Oncol. 2021 Mar;160(3):827-834. doi: 10.1016/j.ygyno.2020.12.024. Epub 2021 Jan 13. Review.</citation>
    <PMID>33451724</PMID>
  </reference>
  <reference>
    <citation>Soja M, Masternak M, Piwowarczyk I, Janas Ł, Szyłło K, Nowak M. Analysis of the results of invasive diagnostic procedures in patients referred to gynecologic department due to abnormal uterine bleeding. Prz Menopauzalny. 2020 Dec;19(4):155-159. doi: 10.5114/pm.2020.101942. Epub 2021 Jan 7.</citation>
    <PMID>33488325</PMID>
  </reference>
  <reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.</citation>
    <PMID>30207593</PMID>
  </reference>
  <reference>
    <citation>Ignatov A, Ortmann O. Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen. Cancers (Basel). 2020 Jul 2;12(7). pii: E1766. doi: 10.3390/cancers12071766. Review.</citation>
    <PMID>32630728</PMID>
  </reference>
  <reference>
    <citation>Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, Gabra H, Paraskevaidis E, Martin-Hirsch P, Tsilidis KK, Kyrgiou M. Risk factors for endometrial cancer: An umbrella review of the literature. Int J Cancer. 2019 Oct 1;145(7):1719-1730. doi: 10.1002/ijc.31961. Epub 2019 Feb 20. Review.</citation>
    <PMID>30387875</PMID>
  </reference>
  <reference>
    <citation>Kruse AJ, Ter Brugge HG, de Haan HH, Van Eyndhoven HW, Nijman HW. Vaginal hysterectomy with or without bilateral salpingo-oophorectomy may be an alternative treatment for endometrial cancer patients with medical co-morbidities precluding standard surgical procedures: a systematic review. Int J Gynecol Cancer. 2019 Feb;29(2):299-304. doi: 10.1136/ijgc-2018-000015. Epub 2019 Jan 18.</citation>
    <PMID>30659027</PMID>
  </reference>
  <reference>
    <citation>Murali R, Delair DF, Bean SM, Abu-Rustum NR, Soslow RA. Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer. J Natl Compr Canc Netw. 2018 Feb;16(2):201-209. doi: 10.6004/jnccn.2017.7066. Review.</citation>
    <PMID>29439179</PMID>
  </reference>
  <reference>
    <citation>Petousis S, Christidis P, Margioula-Siarkou C, Papanikolaou A, Dinas K, Mavromatidis G, Guyon F, Rodolakis A, Vergote I, Kalogiannidis I. Combined pelvic and para-aortic is superior to only pelvic lymphadenectomy in intermediate and high-risk endometrial cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. 2020 Jul;302(1):249-263. doi: 10.1007/s00404-020-05587-2. Epub 2020 May 28.</citation>
    <PMID>32468162</PMID>
  </reference>
  <reference>
    <citation>Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000 Jun;182(6):1506-19.</citation>
    <PMID>10871473</PMID>
  </reference>
  <reference>
    <citation>Reijnen C, Gogou E, Visser NCM, Engerud H, Ramjith J, van der Putten LJM, van de Vijver K, Santacana M, Bronsert P, Bulten J, Hirschfeld M, Colas E, Gil-Moreno A, Reques A, Mancebo G, Krakstad C, Trovik J, Haldorsen IS, Huvila J, Koskas M, Weinberger V, Bednarikova M, Hausnerova J, van der Wurff AAM, Matias-Guiu X, Amant F; ENITEC Consortium, Massuger LFAG, Snijders MPLM, Küsters-Vandevelde HVN, Lucas PJF, Pijnenborg JMA. Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study. PLoS Med. 2020 May 15;17(5):e1003111. doi: 10.1371/journal.pmed.1003111. eCollection 2020 May.</citation>
    <PMID>32413043</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Sherif Abdelkarim Mohammed Shazly</investigator_full_name>
    <investigator_title>Assistant lecturer</investigator_title>
  </responsible_party>
  <keyword>carcinoma of corpus uteri</keyword>
  <keyword>uterine malignancy</keyword>
  <keyword>FIGO staging</keyword>
  <keyword>adenocarcinoma</keyword>
  <keyword>lymphadenectomy</keyword>
  <keyword>hystrectomy</keyword>
  <keyword>prognosis</keyword>
  <keyword>prediction</keyword>
  <keyword>machine learning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

